Richard A. Paulson
President and CEO at Karyopharm Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Karyopharm Therapeutics Inc., 3 years.
Chief executive roles
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 14, 2026 | Karyopharm Therapeutics Inc. | Open-market sale | โ2,203 | $9.50 | $20,929 |
| May 13, 2026 | Karyopharm Therapeutics Inc. | Grant or award | +4,920 | โ | โ |
| Mar 2, 2026 | Karyopharm Therapeutics Inc. | Open-market sale | โ12,361 | $9.41 | $116,317 |
| Feb 5, 2026 | Karyopharm Therapeutics Inc. | Grant or award | +81,060 | โ | โ |
| Oct 15, 2025 | Karyopharm Therapeutics Inc. | Grant or award | +114,285 | โ | โ |
| Sep 15, 2025 | Karyopharm Therapeutics Inc. | Open-market sale | โ1,257 | $6.43 | $8,083 |
| Sep 12, 2025 | Karyopharm Therapeutics Inc. | Grant or award | +2,800 | โ | โ |
| May 6, 2025 | Karyopharm Therapeutics Inc. | Open-market sale | โ236 | $7.12 | $1,680 |
| Apr 4, 2025 | Karyopharm Therapeutics Inc. | Open-market sale | โ245 | $3.74 | $916 |
| Mar 4, 2025 | Karyopharm Therapeutics Inc. | Open-market sale | โ11,694 | $6.29 | $73,555 |
| Feb 28, 2025 | Karyopharm Therapeutics Inc. | Grant or award | +20,000 | โ | โ |
| Feb 4, 2025 | Karyopharm Therapeutics Inc. | Open-market sale | โ4,099 | $0.65 | $2,664 |
| Jan 6, 2025 | Karyopharm Therapeutics Inc. | Open-market sale | โ4,055 | $0.78 | $3,163 |
| Dec 4, 2024 | Karyopharm Therapeutics Inc. | Open-market sale | โ3,620 | $0.81 | $2,932 |
| Nov 5, 2024 | Karyopharm Therapeutics Inc. | Open-market sale | โ3,675 | $0.91 | $3,344 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.